Benzodiazepines (alprazolam, lorazepam, clonazepam, diazepam, and others) work quickly to reduce acute anxiety symptoms by enhancing GABA signaling. They aren't first-line for most anxiety conditions because of risks of physical dependence (which can develop within weeks of daily use), withdrawal (which can be medically serious), and the way they tend to maintain the underlying anxiety pattern over time. They have a real but narrow role in short-term, time-limited situations.
For plain-language detail on any specific medication, including what to expect week by week, side effects, and how to come off it, see our sister publication PsychiatryRx.
A patient who has been on a benzodiazepine daily for two years and is trying to stop is one of the harder situations in outpatient psychiatry. The medication that originally felt like a solution has become its own problem. None of this means benzodiazepines are bad medications. It means they belong in narrow situations, used with a clear plan, and not as long-term anxiety treatment for most patients.
What benzodiazepines do
Benzodiazepines bind to specific sites on GABA-A receptors throughout the brain, enhancing the inhibitory effect of GABA, the brain's main calming neurotransmitter. The clinical result is rapid reduction in anxiety, muscle tension, and sometimes seizure activity. Onset is within thirty minutes to an hour for most. Effects last hours to days depending on the specific medication. PsychiatryRx has an interactive look at what a benzodiazepine does in the brain.
The class includes alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), temazepam (Restoril), and others. They differ mostly in onset speed and duration: alprazolam acts fast and clears fast; clonazepam acts more slowly and lasts longer. The pharmacology of dependence and withdrawal is similar across the class.
The FDA boxed warning
In September 2020, the FDA expanded its boxed warning on benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions. The warning is worth understanding plainly because it shapes how the class is now used.
Physical dependence can develop within several weeks of daily use, even at prescribed therapeutic doses. Physical dependence isn't the same as addiction; it means the body adapts to the medication's presence and will produce withdrawal symptoms if the medication is stopped.
Withdrawal from benzodiazepines can be medically serious. Symptoms include rebound anxiety, insomnia, tremor, sweating, palpitations, and in severe cases seizures. Discontinuation requires a slow, supervised taper, often over months.
Combined use risks. Combining benzodiazepines with opioids substantially increases the risk of fatal respiratory depression and is itself a boxed warning. The combination with alcohol carries similar risks.
Dependence, tolerance, and withdrawal
The single most consequential thing to know about benzodiazepines is that physical dependence develops with regular use, often within several weeks, even at prescribed doses and even when the patient hasn't increased the dose. Dependence isn't the same as addiction, but the body adapts to the medication, and stopping suddenly can produce a withdrawal syndrome.
Tolerance to the anxiolytic effect develops in many patients over weeks to months. The dose that worked for anxiety in the first month may produce less effect by the sixth month. Some patients respond to this by increasing the dose; some respond by adding alcohol or another sedative to recapture the effect. Both responses are common and both produce a more difficult clinical situation.
Withdrawal can be severe. Symptoms include rebound anxiety often worse than the original, sleep disruption, autonomic instability, perceptual changes, and, at the more severe end, seizures and delirium. The withdrawal pattern is sometimes protracted, with symptoms persisting for weeks or months after the last dose. Patients on chronic benzodiazepines should never stop abruptly. The clinical approach is a slow, supervised taper, often over months, with the rate of taper individualized to the patient.
The combination of benzodiazepines with opioids, alcohol, or other sedatives substantially increases the risk of fatal respiratory depression. This combination is one of the most common patterns in overdose deaths.
The FDA strengthened the boxed warning on benzodiazepines in 2020 to reflect these risks. Most current guidelines reserve benzodiazepines for short-term, time-limited use. They aren't first-line for chronic generalized anxiety.
The narrow situations where they make sense
A few situations where a brief course of a benzodiazepine is reasonable.
A single procedural anxiety event (an MRI, a flight for a person with severe flight phobia who can't otherwise complete the trip, a specific medical procedure).
The first two to four weeks of SSRI treatment for severe anxiety, while waiting for the SSRI to take effect. The benzodiazepine is then tapered off as the SSRI begins to work.
Acute alcohol withdrawal, which is a separate medical indication.
Acute, severe situational anxiety in a setting where therapy isn't yet possible, for example, immediately after a traumatic event, used briefly while the patient is connected to appropriate care.
In each case, the use is bounded: a defined duration, a defined number of doses, a clear plan for what comes next.
Why daily long-term use is generally not first-line
Two reasons.
The brain learns from escape. When a person experiences anxiety, takes a benzodiazepine, and feels relief, the brain learns that escape from anxiety requires the medication. The underlying threat sensitivity isn't addressed; the medication has become the safety signal. This pattern tends to make the anxiety worse over time, not better.
Dependence develops. A patient on daily benzodiazepines for months will experience withdrawal if they stop. Many patients realize this only when they try to stop, and find they can't. The taper that follows is often more difficult than the original anxiety.
This isn't a moral failing on anyone's part. It's the predictable result of how the medication interacts with how the brain learns.
Tapering a benzodiazepine
When a patient on long-term benzodiazepines wants to stop, the taper is gradual and supervised. The Ashton Manual, developed by Professor Heather Ashton at Newcastle University, is the most widely referenced patient resource for benzodiazepine tapering. Tapers typically take months, sometimes a year or more, with dose reductions of five to ten percent every two to four weeks. Cross-tapering to a longer-acting benzodiazepine (often diazepam) is sometimes used to smooth the process.
This isn't a do-it-yourself project. Tapering should be done with a clinician familiar with the process.
External references
The NIMH page on mental health medications summarizes the class. The APA practice guidelines discuss the role of benzodiazepines in anxiety care.
Related: How CBT and SSRIs actually work for anxiety · Buspirone for anxiety · Why panic attacks end the way they do